Biomea Fusion 2024 Corporate Presentation

Clinical-stage biopharmaceutical company focused on discovery and development of oral covalent small-molecule drugs to treat genetically defined cancers and metabolic diseases. The company combines validated targets with breakthrough chemistry through its proprietary FUSION™ system, with programs including BMF-219 in Phase II and BMF-500 in Phase I development.